All In Biotech

Drug Trial Radar · NCT01894958

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome

Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jan 2014

Primary completion

Sep 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
Jul 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 12 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.

Conditions

  • Fragile X Syndrome

Interventions

  • NNZ-2566Drug

    Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

  • PlaceboDrug

    Strawberry flavored solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Through to Day 56

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis MIND Institute

    Sacramento, California

  • Children's Hospital Colorado

    Denver, Colorado

  • Children's National Hospital

    Washington D.C., District of Columbia

  • Emory University

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University of Nebraska

    Omaha, Nebraska

  • Mount Sinai School of Medicine

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Autism & Developmental Medicine Institute Geisinger Health System

    Lewisburg, Pennsylvania

  • Suburban Research Associates

    Media, Pennsylvania

  • Greenwood Genetic Center

    Greenwood, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Children's Hospital

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.